$ERAS mention timeline

Erasca. Every tracked FinTwit mention of $ERAS, newest first. 12 mentions since the first on Nov 19, 2025. See the price chart.

June 2026 · 1 mention

Jun 1
Jacob Plieth — $ERAS is again the way to trade positive $RVMD news? #Asco26 https://t.co/RCyQGOobHF↗

Apr 29
Jacob Plieth — Looks like $ERAS was taking lessons from $AZN $DSNKY https://t.co/ukxzGGCdas↗
Apr 27
Adam Feuerstein ✡️ — $ERAS pan-Ras data update this afternoon after market close. also, $RVMD sent Erasca a letter claiming ERAS-0015 violates certain RevMed patents. https://t.co/QTmyUhT89n↗
Apr 23
Adam Feuerstein ✡️ — @Banana_Oncology As I mentioned, companies usually set their own benchmark for a reason. What will you use from $RVMD as a comparator to the upcoming $ERAS data?↗
Apr 23
Adam Feuerstein ✡️ — This week's Biotech Scorecard: Erasca $ERAS is the poor man's $RVMD (even tho $7B is far from impoverished) Can it be biotech's next big thing? Pan-Ras data next month, right in f…↗

Dec 22
Jacob Plieth — $AZN follows $LLY $PFE $AMGN $ONC & $ALPMF into pan-KRAS, but should it be looking more to pan-RAS approaches like $RVMD & $ERAS? Via @ApexOnco -> https://t.co/MioOWziu…↗
Dec 22
Jacob Plieth — @NotGenentech @bioinvestor24 Here's a list of just the clinical pan-RAS & pan-KRAS assets from Oncologypipeline $RVMD $LLY $ONC $RHHBY $PFE $ERAS $AZN $AMGN $ALPMF https://t.co…↗
Dec 22
Jacob Plieth — @NotGenentech @bioinvestor24 $ERAS got that from Joyo for... $12.5m!↗

Nov 19
Jacob Plieth — @s86CoffeeDev @houndcl @financebully @avidresearch @Banana_Oncology $ERAS says ERAS-0015 uses different scaffold vs daraxonrasib. Not sure if that circumvents $RVMD patent.↗
Nov 19
Jacob Plieth — Each will comprise "dozens of patients". Goal for ERAS-0015 is "comparable" safety to $RVMD and comparable efficacy at say half daraxonrasib dose $ERAS #Jefferies25↗
Nov 19
Jacob Plieth — $ERAS David Chacko reiterating timelines for ERAS-0015 & ERAS-4001: first ph1 monorx dose-escalation data for both expected in calendar 2026 #Jefferies25↗